AI Article Synopsis
- Previous research identified immune cells in ruminant placentas, showing significant CD79 labeling in cells that looked like trophoblasts.
- Placentomes from cattle, sheep, and water buffaloes were studied using immunohistochemistry with antibodies targeting B lymphocytes and trophoblast cells.
- The majority of CD79+ cells also expressed placental lactogen or cytokeratin but were negative for CD21 and MHC class II, indicating they likely don't originate from B cells, though their potential immunological role remains unclear.
Article Abstract
Previous work carried out to characterise different immune cells in ruminant placentas found strong CD79 nuclear labelling in cells histologically resembling trophoblast cells. In the attempt to characterize this cell population, placentomes collected from cattle, sheep and water buffaloes were examined by immunohistochemistry with single and double labelling using monoclonal antibodies (mAb) against B lymphocytes and trophoblast cells. Most CD79 + cells co-expressed placental lactogen or cytokeratin and were CD21 and MHC class II negative strongly suggesting they do not have a B cell origin. However, a potential immunological role of these cells cannot be ruled out and it is currently unknown if the findings described may have an impact on physiological knowledge, health, and or diseases pathogenesis in ruminants.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.vetimm.2019.109942 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Molecular Profiling Identifies CD49d and CD79b as Predictive Markers for Acquired Acalabrutinib Resistance in Patients With Chronic Lymphocytic Leukemia.
Hematol Oncol
January 2025
Hematology, Oncology R&D, AstraZeneca, Cambridge, UK.
Contemporary studies of Bruton tyrosine kinase inhibitor (BTKi) resistance focus on mutations in the B-cell receptor (BCR) pathway, but alternative mechanisms of resistance remain undefined. Here, we sought to identify novel predictive markers of acquired resistance to acalabrutinib, a second-generation BTKi, in patients with chronic lymphocytic leukemia (CLL). Clinical samples from 41 patients with relapsed/refractory or treatment-naive CLL receiving acalabrutinib as part of a clinical trial (NCT02029443) were divided into two groups: those who continued to respond to treatment (NP, n = 23) and those who developed progressive disease on acalabrutinib therapy (PD, n = 18).
View Article and Find Full Text PDFPreclinical development of three novel CARs targeting CD79b for the treatment of non-Hodgkin's lymphoma and characterization of the loss of the target antigen.
J Immunother Cancer
December 2024
Department of Experimental Hematology, Health Research Institute of the Jimenez Diaz Foundation, UAM, Madrid, Spain, UAM, Madrid, Spain
Background: Infusion of T cells modified with a chimeric antigen receptor (CAR) targeting CD19 has achieved exceptional responses in patients with non-Hodgkin's lymphoma (NHL), which led to the approval of CAR targeting CD19 (CART19) (Axi-cel and Liso-cel) as second line of treatment for adult patients with relapsed/refractory NHL. Unfortunately, 60% of patients still relapse after CART19 due to either a loss of expression of the target antigen (CD19) in the tumor cell, observed in 27% of relapsed patients, a limited CAR-T persistence, and additional mechanisms, including the suppression of the tumor microenvironment. Clinic strategies to prevent target antigen loss include sequential treatment with CARs directed at CD20 or CD22, which have caused loss of the second antigen, suggesting targeting other antigens less prone to disappear.
View Article and Find Full Text PDFTransmissible venereal tumour with encephalic metastasis in dogs.
J Comp Pathol
December 2024
Postgraduate Program in Animal Science and Health, Federal University of Campina Grande, Patos, Paraíba, Brazil.
From January 2000 to December 2023 the Laboratory of Animal Pathology of the Federal University of Campina Grande received 6,218 canine autopsy and biopsy submissions, with six (0.09%) autopsy cases diagnosed as transmissible venereal tumour (TVT) with encephalic metastases. The mean age of affected dogs (four females and two males) was 7 years.
View Article and Find Full Text PDFSpheroid culture to select theoretical therapeutic drugs in intravascular large B-cell lymphoma.
Cancer Sci
January 2025
Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
Article Synopsis
- - Intravascular large B-cell lymphoma (IVLBCL) is a rare cancer impacting blood vessel linings, with recent research focusing on genetic mutations that could guide targeted drug therapies.
- - Researchers developed a new ex vivo culture system to grow IVLBCL cells from patient-derived xenograft models, allowing for longer cell culture durations and drug testing.
- - Their findings showed that while carfilzomib's effectiveness was hard to determine due to toxicity, ibrutinib proved to be effective and comparable to standard chemotherapy, supporting its potential use in IVLBCL treatment.
Immunophenotypic properties association of CLL and ALL patient cells by flow cytometry analysis.
J Taibah Univ Med Sci
October 2024
Department of Biology, College of Science, Salahaddin University-Erbil, Erbil, Kurdistan Region, Iraq.
Article Synopsis
- Chronic lymphocytic leukemia (CLL) and acute lymphoblastic leukemia (ALL) are blood cancers affecting lymphocytes, which can be diagnosed through flow cytometry, focusing on cell surface markers like CD19.
- The study aimed to analyze the relationship between CD19-positive cell counts and other CD antigens in patients diagnosed with CLL and ALL.
- Results indicated that while age and sex did not impact CD19-positive cell counts, CLL patients showed strong correlations between CD19 and other markers (CD5, CD20, CD23, CD200), while ALL patients showed similar correlations with CD79 and CD99, with higher CD19 counts observed in both groups.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!